On the heels of its landmark valvular heart disease (VHD) prevalence abstract published in Journal of the American College of Cardiology (JACC), egnite, Inc. announced that it has expanded the company’s focus beyond structural heart disease into cardiovascular (CV) disease, starting with atrial fibrillation (AF).
News | Atrial Fibrillation
egnite, Inc. Expands into Cardiovascular Disease Supported by New Data on the State of Care for Patients with Atrial Fibrillation

May 17, 2022 — On the heels of its landmark valvular heart disease (VHD) prevalence abstract published in Journal of the ...

Home May 17, 2022
Home
Seamless integration and communication between Philips Ultrasound System - EPIQ CVxi - and Philips Image Guided Therapy System - Azurion - supports efficient fusion-imaging workflow for minimally-invasive treatment of structural heart disease
News | Structural Heart
Philips EchoNavigator Helps Interventional Teams Treat Structural Heart Disease

May 16, 2022 — Philips, a global leader in health technology, announced at EuroPCR (17 - 20 May 2022, Paris, France) the ...

Home May 16, 2022
Home
Boston Scientific announced that Peter M. “Pete” Nicholas, co-founder and former CEO of Boston Scientific from 1979 to 1999 and a corporate visionary in the minimally invasive surgery industry, passed away peacefully on May 14 just a few days before his 81st birthday. 
News | Cardiovascular Business
Boston Scientific Co-founder and Former CEO Passes Away

May 16, 2022 — Boston Scientific announced that Peter M. “Pete” Nicholas, co-founder and former CEO of Boston Scientific ...

Home May 16, 2022
Home
Key members of the research collaboration: (from left) Prof Roger Foo (Programme Director, ATTRaCT, and Senior Group Leader, GIS), Dr Karin Conde-Knape (Senior Vice President, Global Drug Discovery, Novo Nordisk), Dr Rasmus Rabøl (Corporate Vice President, Global Translation, Novo Nordisk), Dr Natasha Michaelsen (Principal Scientist, Global Translation, Novo Nordisk), Prof Mark Richards (Director, Cardiovascular Research Institute, NUS, and Deputy Director, National University Heart Centre), Prof Derek Haus
News | Heart Failure
A*STAR, NHCS, NUS, and Novo Nordisk to Collaborate on Cardiovascular Disease Research

May 16, 2022 — The Agency for Science, Technology and Research’s (A*STAR) Genome Institute of Singapore (GIS) and ...

Home May 16, 2022
Home
A substantial proportion of patients with COVID and shock had low CI despite preserved EF, suggesting underfilling of the LV, but this proportion was smaller in W2. This difference could not be explained by changes in PEEP between cohorts. This suggests that fluid management strategies may have been more aggressive in W2.
News | Coronavirus (COVID-19)
New Report Published Comparing Hemodynamics of Cardiac Shock in COVID-19 Patients in Pandemic’s First Vs. Second Wave

May 16, 2022 — A new report by a team of cardiologists from the Heart & Vascular Hospital, Hackensack Meridian ...

Home May 16, 2022
Home
Pump housing and impeller design. (A): (left) Axial flow pump: HeartMate II LVAD (taken from Figure 2 in the HeartMate II left ventricular assist system instructions for use). (B) (right) Centrifugal flow pump: HeartWare assist device (taken from Figure 2 in the HeartWare assist device patient manual).
News | Heart Failure
Study Finds that Concurrent Tricuspid Valve Surgery and Left Ventricular Assist Device Implantation do not Appear to Lower the Incidence of Right Heart Failure

May 16, 2022 — Right heart failure (RHF) continues to be a major source of morbidity and mortality following left ...

Home May 16, 2022
Home
CRF Meeting Covering Structural Heart Disease Innovations Will Take Place June 8-10
News | TVT
Late-Breaking Science Announced for TVT 2022

May 16, 2022 — The Cardiovascular Research Foundation (CRF) announced that TVT: The Structural Heart Summit will feature ...

Home May 16, 2022
Home
Mavacamten estimated sales just shy of $1 billion if approved for common cardiomyopathy subtype, says GlobalData
News | Pharmaceuticals
Bristol Myers Squibb’s Mavacamten Poised to Stand unchallenged

May 13, 2022 — Bristol Myers Squibb’s mavacamten will stand rather unchallenged in the hypertrophic cardiomyopathy (HCM) ...

Home May 13, 2022
Home
Acutus Medical, an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced successful completion of patient enrollment in the company’s AcQForce Flutter Investigational Device Exemption (IDE) clinical trial which enrolled 110 patients at 21 sites globally
News | Ablation Systems
Acutus Medical Completes Enrollment in IDE Trial with its AcQBlate FORCE Sensing Ablation System

May 13, 2022 — Acutus Medical, an arrhythmia management company focused on improving the way cardiac arrhythmias are ...

Home May 13, 2022
Home
Woon-Hong Yeo has developed a smarter stent. Georgia Tech Photo
News | Stents
Georgia Tech Researchers Develop Wireless Implantable Vascular Monitoring System

May 13, 2022 — Vascular diseases are public enemy number one: the leading killers worldwide, accounting for nearly a ...

Home May 13, 2022
Home
The Neurescue device is an FDA-approved device currently in use for patients with severe bleeding which will now be used in a new study to help increase survival rate for those who experience in-hospital cardiac arrests
News | Sudden Cardiac Arrest
MemorialCare Long Beach Medical Center Only Site in Nation to Offer ARISE-Study – New Experimental Treatment for In-Hospital Cardiac Arrest

May 13, 2022 — The MemorialCare Heart & Vascular Institute at Long Beach Medical Center has been designated the only ...

Home May 13, 2022
Home
Training program is open to underrepresented groups including female, Black, Native American, Asian, South Asian, Hispanic and non-binary cardiologists
News | Cardiovascular Business
Abbott and Women as One Partner to Help More Underrepresented Physicians Lead Clinical Trials

May 12, 2022 — Abbott announced a new partnership with Women as One to launch a new program designed to train more ...

Home May 12, 2022
Home
The global cardiogenic shock market was valued at US$ 3.29 Bn in 2021, and is expected to reach US$ 6.32 Bn by 2032, expanding at a CAGR of 6.2% over the 2022-2032 time frame.
Feature | Cardiogenic Shock
Cardiogenic Shock Market Outlook

The global cardiogenic shock market was valued at US$ 3.29 Bn in 2021, and is expected to reach US$ 6.32 Bn by 2032 ...

Home May 12, 2022
Home
Integrated patch offers ECG, heart rate, respiratory rate, and blood pressure monitoring for commercial research and development
News | Remote Monitoring
Vivalink Announces World’s First Multi-Vital Blood Pressure Patch for Remote Patient Monitoring

May 12, 2022 — Vivalink, a leading provider of digital healthcare solutions, announced availability of the world’s first ...

Home May 12, 2022
Home
Peter Mackrell, MD
News | Cardiovascular Business
Board Certified Vascular Surgeon Joins NDA Partners as Expert Consultant

May 12, 2022 — NDA Partners General Manager, Eric Fish, announced today that Peter Mackrell, MD, a board certified ...

Home May 12, 2022
Home
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now